Ishihara K, Hasegawa T, Okazaki M, Katakami N, Sakamoto H, Umeda B, Nakai H
Department of Respiratory Diseases, Kobe City General Hospital.
Intern Med. 1995 Feb;34(2):77-80. doi: 10.2169/internalmedicine.34.77.
We retrospectively studied the use of inhaled corticosteroids in patients who experienced near fatal episodes (NFE) to determine whether such therapy reduces the risk of death. Forty-eight patients who had near fatal episodes of asthma between January 1981 and December 1989 were divided into two groups. Group A comprised 19 patients who received beclomethasone dipropionate (BDP) daily (mean dose of BDP:687 micrograms/day: 200-2,000) following NFE, and Group B, 28 patients who did not take BDP or who took less than 6 mg BDP/month. During the follow-up period (Group A:82.9 months, Group B:66.2 months), no patients in Group A died, but eight deaths occurred in Group B (mean period between near fatal episode and death was 31.5 months: 12-66). These results suggest that the regular use of inhaled corticosteroids, even at low doses, may reduce the risk of death in patients who experience NFE.
我们回顾性研究了吸入性糖皮质激素在经历过濒死发作(NFE)的患者中的使用情况,以确定这种治疗是否能降低死亡风险。1981年1月至1989年12月期间经历过哮喘濒死发作的48例患者被分为两组。A组包括19例在濒死发作后每日接受二丙酸倍氯米松(BDP)治疗的患者(BDP平均剂量:687微克/天,范围为200 - 2000微克),B组包括28例未服用BDP或每月服用BDP少于6毫克的患者。在随访期间(A组:82.9个月,B组:66.2个月),A组无患者死亡,而B组有8例死亡(濒死发作至死亡的平均间隔时间为31.5个月,范围为12 - 66个月)。这些结果表明,即使是低剂量的吸入性糖皮质激素常规使用,也可能降低经历过濒死发作患者的死亡风险。